专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20130295095A1 MONOCLONAL ANTIBODIES TARGETING AMYLOID BETA OLIGOMERS 有权
标题翻译：单克隆抗体靶向AMYLOID BETA寡聚体
公开(公告)号：US20130295095A1
公开(公告)日：2013-11-07
申请号：US13701758
申请日：2011-06-03
申请人： Thomas Bayer , Oliver Wirths , Henrik Martens , Christian Erck
发明人： Thomas Bayer , Oliver Wirths , Henrik Martens , Christian Erck
IPC分类号： C07K16/18
CPC分类号： C07K16/18 , A61K2039/505 , C07K2317/32 , C07K2317/33 , C07K2317/76
摘要： The invention relates to binding molecules capable of specifically recognizing soluble oligomers of N-terminal truncated Aβ starting with pyroglutamate (AβρE), pharmaceutical compositions comprising same, and their respective therapeutic uses. Particularly, the invention relates to an antibody molecule capable of specifically recognizing Aβ oligomers, wherein said antibody binds and/or detects an epitope as bound and/or detected by antibody PG3-38 9D5H6 as deposited under DSM AC-C3056. Further, the invention provides a method of inhibiting the formation or the seeding effect of said AβρE oligomers, and a method for identifying agents useful in the treatment and/or prevention of an amyloid-related disorder as well as methods of diagnosing a subject suspected of suffering from a disease associated with amyloidogenesis and/or amyloid plaque formation and to methods of monitoring the efficacy of a treatment of a disease associated with amyloidogenesis and/or amyloid-plaque formation characterized by the presence of Aβ oligomers in a subject.
摘要翻译：本发明涉及能够特异性识别由焦谷氨酸（AbetarhoE）开始的N-末端截短的Abeta的可溶性低聚物，包含其的药物组合物及其各自的治疗用途的结合分子。特别地，本发明涉及能够特异性识别Aβ寡聚体的抗体分子，其中所述抗体结合和/或检测由DSM AC-C3056沉积的抗体PG3-38 9D5H6结合和/或检测的表位。此外，本发明提供抑制所述AbetarhoE寡聚体的形成或播种作用的方法，以及用于鉴定可用于治疗和/或预防淀粉样蛋白相关病症的药剂的方法以及诊断疑似患者的方法患有与淀粉样变性和/或淀粉样蛋白斑形成相关的疾病，以及监测治疗与淀粉样变性和/或淀粉样蛋白斑形成有关的疾病的功效的方法，其特征在于受试者中存在Aβ寡聚体。

2. 发明授权

US09204623B2 Transgenic mouse model expressing amyloid β 4-42 peptide 有权
标题翻译：表达淀粉样蛋白的转基因小鼠模型 4-42肽
公开(公告)号：US09204623B2
公开(公告)日：2015-12-08
申请号：US13702390
申请日：2010-06-08
申请人： Thomas Bayer , Oliver Wirths
发明人： Thomas Bayer , Oliver Wirths
IPC分类号： A01K67/00 , G01N33/00 , A01K67/027 , C07K14/47 , C12N15/85
CPC分类号： A01K67/0278 , A01K67/0275 , A01K2217/052 , A01K2227/105 , A01K2267/0312 , C07K14/4711 , C12N15/8509
摘要： The present invention describes a novel transgenic mouse model for the common sporadic form of Alzheimer's disease. More particularly, the invention relates to a nucleotide sequence encoding Aβ 4-42 in functional linkage with at least a promoter, signal peptide sequence and a polyadenylation signal sequence, a cell and a transgenic non-human animal comprising said nucleotide sequence, and their respective use in screening methods.
摘要翻译：本发明描述了用于常见散发形式的阿尔茨海默氏病的新型转基因小鼠模型。更具体地，本发明涉及编码A＆bgr的核苷酸序列; 4-42，其与至少一种启动子，信号肽序列和多聚腺苷酸化信号序列功能连接，包含所述核苷酸序列的细胞和转基因非人动物，以及它们在筛选方法中的各自用途。

3. 发明授权

US08795664B2 Monoclonal antibodies targeting amyloid beta oligomers 有权
标题翻译：针对淀粉样β寡聚体的单克隆抗体
公开(公告)号：US08795664B2
公开(公告)日：2014-08-05
申请号：US13701758
申请日：2011-06-03
申请人： Thomas Bayer , Oliver Wirths , Henrik Martens , Christian Erck
发明人： Thomas Bayer , Oliver Wirths , Henrik Martens , Christian Erck
IPC分类号： A61K39/395 , C07K16/18 , C12N5/20
CPC分类号： C07K16/18 , A61K2039/505 , C07K2317/32 , C07K2317/33 , C07K2317/76
摘要： The invention relates to binding molecules capable of specifically recognizing soluble oligomers of N-terminal truncated Aβ starting with pyroglutamate (AβρE), pharmaceutical compositions comprising same, and their respective therapeutic uses. Particularly, the invention relates to an antibody molecule capable of specifically recognizing Aβ oligomers, wherein said antibody binds and/or detects an epitope as bound and/or detected by antibody PG3-38 9D5H6 as deposited under DSM AC-C3056. Further, the invention provides a method of inhibiting the formation or the seeding effect of said AβρE oligomers, and a method for identifying agents useful in the treatment and/or prevention of an amyloid-related disorder as well as methods of diagnosing a subject suspected of suffering from a disease associated with amyloidogenesis and/or amyloid plaque formation and to methods of monitoring the efficacy of a treatment of a disease associated with amyloidogenesis and/or amyloid-plaque formation characterized by the presence of Aβ oligomers in a subject.
摘要翻译：本发明涉及能够特异性识别N-末端截短的A和Bgr的可溶性低聚物的结合分子; 由焦谷氨酸（A＆Bgr; E）开始，包含其的药物组合物及其各自的治疗用途。特别地，本发明涉及能够特异性识别A＆bgr的抗体分子; 寡聚体，其中所述抗体结合和/或检测由DSM AC-C3056沉积的抗体PG3-38 9D5H6结合和/或检测的表位。此外，本发明提供了抑制所述Aβ和β-寡聚体的形成或播种作用的方法，以及用于鉴定可用于治疗和/或预防淀粉样蛋白相关病症的药剂的方法以及诊断方法怀疑患有与淀粉样变性和/或淀粉样蛋白斑形成相关的疾病的受试者以及监测与淀粉样变性和/或淀粉样蛋白斑形成有关的疾病的治疗功效的方法，其特征在于存在Aβ和B淀粉样蛋白。受试者中的寡聚体。

4. 发明申请

US20130179998A1 TRANSGENIC MOUSE MODEL EXPRESSING AMYLOID BETA 4-42 PEPTIDE 有权
标题翻译：转基因鼠模型表达4-42肽的淀粉样蛋白
公开(公告)号：US20130179998A1
公开(公告)日：2013-07-11
申请号：US13702390
申请日：2010-06-08
申请人： Thomas Bayer , Oliver Wirths
发明人： Thomas Bayer , Oliver Wirths
IPC分类号： A01K67/027
CPC分类号： A01K67/0278 , A01K67/0275 , A01K2217/052 , A01K2227/105 , A01K2267/0312 , C07K14/4711 , C12N15/8509
摘要： The present invention describes a novel transgenic mouse model for the common sporadic form of Alzheimer's disease. More particularly, the invention relates to a nucleotide sequence encoding Aβ 4-42 in functional linkage with at least a promoter, signal peptide sequence and a polyadenylation signal sequence, a cell and a transgenic non-human animal comprising said nucleotide sequence, and their respective use in screening methods.
摘要翻译：本发明描述了用于常见散发形式的阿尔茨海默氏病的新型转基因小鼠模型。更具体地，本发明涉及编码与至少启动子，信号肽序列和多聚腺苷酸化信号序列，细胞和包含所述核苷酸序列的细胞和转基因非人动物的功能性连接的Aβ4-42的核苷酸序列，以及它们各自的用于筛选方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式